News >

Biosimilars Expected to Become More Widespread in US Oncology Market

Caroline Seymour
Published: Tuesday, Jan 21, 2020

Francisco J. Esteva, MD, PhD, director, Breast Medical Oncology Program, and research professor, Department of Pathology, NYU Langone Health's Perlmutter Cancer Center

Francisco J. Esteva, MD, PhD

Following several demonstrations of equivalent safety and efficacy with their reference products, Francisco J. Esteva, MD, PhD, anticipates that biosimilars will take on a greater role in cancer medicine due to their cost-savings potential.

“Several clinical trials have shown that trastuzumab (Herceptin) biosimilars are as effective and as safe as the originator trastuzumab,” said Esteva. “I believe biosimilars will be used in breast cancer because of the cost benefit they can provide.”

To date, 5 biosimilars for trastuzumab (Herceptin) have received regulatory approval: MYL-1401O (Ogivri; trastuzumab-dkst), CT-P6 (Herzuma; trastuzumab-pkrb), SB3 (Ontruzant; trastuzumab-dttb), PF-05280014 (Trazimera; trastuzumab-qyyp), and ABP 980 (Kanjinti; trastuzumab-anns).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication